

What Is Claimed Is:

1. An agent for treating or preventing hepatic disease containing menatetrenone as an active ingredient thereof.

5

2. The agent according to claim 1, wherein the hepatic disease is hepatic cancer.

3. The agent according to claim 2, wherein the hepatic
10 cancer is des- γ -carboxy prothrombin positive hepatic cancer.

4. The agent according to any one of claims 1 through 3, wherein the agent improves prognosis after hepatic cancer treatment.

15 5. The agent according to claim 4, wherein the agent is an agent that inhibits occurrence of portal venous invasion.

6. An agent for inhibiting occurrence of portal venous invasion containing menatetrenone as an active ingredient thereof.

20

7. An agent for improving survival rate after hepatic cancer treatment containing menatetrenone as an active ingredient thereof.

8. An agent for inhibiting recurrence of hepatocellular
25 carcinoma containing menatetrenone as an active ingredient thereof.

9. An agent for reducing des- γ -carboxy prothrombin level containing menatetrenone as an active ingredient thereof.

10. A method of preventing portal venous invasion,
5 comprising administering to a patient an effective dose of a medicine containing menatetrenone as an active ingredient thereof.

11. A method of inhibiting recurrence of hepatocellular carcinoma, comprising administering to a patient an effective dose
10 of a medicine containing menatetrenone as an active ingredient thereof.

12. A method of modulating the level of des- γ -carboxy prothrombin in the blood of a patient, comprising administering
15 to the patient an effective dose of a medicine containing menatetrenone as an active ingredient thereof.

13. A use of menatetrenone for manufacturing an agent for inhibiting occurrence of portal venous invasion.
20

14. A use of menatetrenone for inhibiting recurrence of hepatocellular carcinoma.

15. An agent for treating or preventing hepatic disease
25 containing a vitamin K as an active ingredient thereof.